Related Experiment Video
Updated: Apr 30, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges
Sophie Paczesny1, Sonali P Barwe2, Anilkumar Gopalakrishnapillai2
1Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
T cell-engaging bispecific antibodies (T-BsAbs) have revolutionized immunotherapy for hematologic malignancies, showing promise in lymphoid cancers and myeloma. However, their application in myeloid malignancies like acute myeloid leukemia (AML) faces challenges due to myelotoxicity and limited target specificity. Here, we review the current landscape of T-BsAb development for myeloid diseases, detailing target antigens, antibody engineering strategies, and clinical trial outcomes. We discuss advances in bispecific antibody formats designed to enhance efficacy and reduce toxicity, alongside emerging therapeutic combinations. Our synthesis highlights the complexity of targeting myeloid malignancies while sparing normal hematopoietic cells. These insights underscore the potential of refined T-BsAb approaches to improve treatment specificity and efficacy in AML and related disorders, informing future therapeutic strategies and clinical development.
T cell-engaging bispecific antibodies (T-BsAbs) have revolutionized immunotherapy for hematologic malignancies, showing promise in lymphoid cancers and myeloma. However, their application in myeloid malignancies like acute myeloid leukemia (AML) faces challenges due to myelotoxicity and limited target specificity. Here, we review the current landscape of T-BsAb development for myeloid diseases, detailing target antigens, antibody engineering strategies, and clinical trial outcomes. We discuss advances in bispecific antibody formats designed to enhance efficacy and reduce toxicity, alongside emerging therapeutic combinations. Our synthesis highlights the complexity of targeting myeloid malignancies while sparing normal hematopoietic cells. These insights underscore the potential of refined T-BsAb approaches to improve treatment specificity and efficacy in AML and related disorders, informing future therapeutic strategies and clinical development.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

